![Pieter van Rompay](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 6 M $ al 31/05/2026
Pieter van Rompay has worked as a Director at EXO Biologics SA since 2019 and as a Managing Director & Director at Labo Phytophar NV since 2020.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
Hyloris Pharmaceuticals SA
 Hyloris Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products by reformulating well-known drugs 3,72 % | 31/12/2024 | 1.041.613 ( 3,72 % ) | 6 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
EXO Biologics SA
 EXO Biologics SA BiotechnologyHealth Technology Operates as a biotechnology company | Director/Miembro de la Junta | 29/08/2019 |
Labo Phytophar NV
 Labo Phytophar NV Food: Specialty/CandyConsumer Non-Durables Manufactures medicaments, condiments and seasonings | Director Ejecutivo | 30/10/2019 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
| Empresas privadas | 2 |
|---|---|
EXO Biologics SA
EXO Biologics SA BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
Labo Phytophar NV
Labo Phytophar NV Food: Specialty/CandyConsumer Non-Durables Manufactures medicaments, condiments and seasonings | Consumer Non-Durables |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
